Previous studies have shown that physical inactivity is associated with a higher prevalence of primary headache disorders, particularly migraine. However, heterogeneous associations regarding sex, headache subtype, physical activity intensity, and headache attack frequency have been reported. In addition, no validated questionnaires on physical activity nor standardised definitions of physical activity have been used. Most studies investigated physical activity levels in leisure time and none in commuting time. The current cross-sectional analysis of the ELSA-Brasil cohort aimed to implement all guidelines.
Almost all 15,000 participants (54.4% women) provided data on physical activity levels and headache. Dr Arão Oliveira (University of São Paulo, Brazil) presented the data. The 1-year crude headache prevalence was 70.4%, with migraine present in 8.4% of respondents. Overall, participants with headache disorders were younger and had higher socioeconomic status.
People with (probable) migraine had a lower cardiovascular risk profile, were more physically inactive compared with the ‘no headache’ group, and had a higher attack frequency compared with persons with other headache disorders, such as tension-type headache (TTH). People with TTH showed less physical activity in the commuting time.
In the adjusted models, physical inactivity in leisure time was associated with a higher prevalence of definite migraine (OR 1.32) and probable migraine (OR 1.33) in the whole cohort. Sex differences were observed, with OR 1.20 for definite and OR 1.29 for probable migraine in women, whereas in men, it was only associated with probable migraine (OR 1.40). Physical inactivity in the commuting time also showed a sex difference: in men, it was associated with probable TTH (OR 1.33); in women, it was inversely associated with definite migraine (OR 0.79) and probable migraine (OR 0.80).
By evaluating the intensity of physical activity, the researchers found that vigorous inactivity in leisure time was associated both with definite migraine (OR 1.36) and probable migraine (OR 1.37). There was a strong linear trend for the association between physical inactivity and headache attack frequency (P-value for trend <0.001). These findings have implications on tailoring the prescriptions of physical activity in people with headache disorders.
- Oliveira AB, et al. Physical inactivity and headache disorders in the ELSA-Brasil cohort: A cross-sectional analysis. AL017, IHC 2021, 8–12 September.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Increased suicidal attempts and risks of ideation in medication-overuse headache Next Article
Voice change and throat swelling are cranial autonomic symptoms in primary headache »
« Increased suicidal attempts and risks of ideation in medication-overuse headache Next Article
Voice change and throat swelling are cranial autonomic symptoms in primary headache »
Table of Contents: IHC 2021
Featured articles
Letter from the Editor
COVID-19
Telemedicine beneficial for headache care during the pandemic
Comparison of headaches after SARS-CoV-2 vaccination
Grey matter cortical changes in patients with persistent headache after COVID-19
Increased risk of cerebral venous thrombosis in COVID-19
Patient Perception and Symptoms
Predictors of health-related quality of life in cluster headache
Dry eye disease is more prevalent in migraine
Voice change and throat swelling are cranial autonomic symptoms in primary headache
Association between physical inactivity and headache disorders
Increased suicidal attempts and risks of ideation in medication-overuse headache
Cardioembolic Comorbidities
AI-enabled ECG algorithm predicts atrial fibrillation risk in migraine
Migraine may not be a risk factor for stroke
Imaging
Functional brainstem somatotopy of the trigeminal nerve during nociception
Morphological changes in cluster headache between attacks
Interictal pontine metabolism in migraine patients without aura
Genome-Wide Association Studies
Largest genome-wide association study of migraine to date
Robust evidence that cluster headache has a genetic basis
Pharmacological Treatment
Insights in drug-drug interactions facilitate rational polypharmacy
Rimegepant confers long-term improvements in MMDs
First real-world effectiveness data of erenumab is promising
Galcanezumab effective in patients with episodic or chronic cluster headache
Central effects and affected somatosensory processing with galcanezumab in migraine
Long-term safety and tolerability of atogepant in migraine
Non-Pharmacological Treatment
Occipital nerve stimulation effective and safe in chronic cluster headache
Related Articles
March 12, 2021
Many nonpharmacological options to treat pediatric migraine
August 27, 2019
Factors influencing choice of prophylactic migraine therapy
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com